Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A.

Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.

Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

etoposide in small cell lung cancer.

Selection of radioresistant cells by vitamin A deficiency in a small cell lung cancer cell line.

Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line.

Longitudinal time-dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line.

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer.

ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.

Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer.

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer.

Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.

vincristine therapy in small cell lung cancer.

etoposide therapy in non-small cell lung cancer.

oral etoposide therapy in non-small cell lung cancer.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.

Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.

Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.

Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.

Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.

Suggest Documents

Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.

Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

etoposide in small cell lung cancer.

Selection of radioresistant cells by vitamin A deficiency in a small cell lung cancer cell line.

Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line.

Longitudinal time-dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line.

Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer.

ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.

Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer.

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer.

Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.

vincristine therapy in small cell lung cancer.

etoposide therapy in non-small cell lung cancer.

oral etoposide therapy in non-small cell lung cancer.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

Phase I study with combination therapy of pirarubicin, etoposide, and vincristine in small-cell lung cancer.

Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.

Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.

Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively.

Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.

Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A.

Recommend Documents

Follow Us